256 related articles for article (PubMed ID: 23328959)
21. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis.
Shen C; Shih YC; Xu Y; Yao JC
Cancer; 2014 Jul; 120(13):2039-49. PubMed ID: 24676892
[TBL] [Abstract][Full Text] [Related]
22. A prospective study of carcinoid crisis with no perioperative octreotide.
Wonn SM; Ratzlaff AN; Pommier SJ; McCully BH; Pommier RF
Surgery; 2022 Jan; 171(1):88-93. PubMed ID: 34226047
[TBL] [Abstract][Full Text] [Related]
23. mTOR inhibitor therapy for patients with carcinoid.
Rindi G; Caplin M
Lancet; 2011 Dec; 378(9808):1978-1980. PubMed ID: 22119494
[No Abstract] [Full Text] [Related]
24. Sandostatin desensitization--a strategy useful for patients with carcinoid tumors, intolerant to sandostatin.
Vinjamaram S; Iyer R
Cancer Chemother Pharmacol; 2011 Jul; 68(1):225-6. PubMed ID: 20922390
[TBL] [Abstract][Full Text] [Related]
25. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
[TBL] [Abstract][Full Text] [Related]
26. Carcinoid crisis induced by repeated abdominal examination.
Morrisroe K; Sim IW; McLachlan K; Inder WJ
Intern Med J; 2012 Mar; 42(3):342-4. PubMed ID: 22432991
[No Abstract] [Full Text] [Related]
27. Long-acting formulations of somatostatin analogues.
Anthony LB
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S216-8. PubMed ID: 10604134
[TBL] [Abstract][Full Text] [Related]
28. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors.
Trendle MC; Moertel CG; Kvols LK
Cancer; 1997 Feb; 79(4):830-4. PubMed ID: 9024721
[TBL] [Abstract][Full Text] [Related]
29. Somatostatin analogue phase I trials in neuroendocrine neoplasms.
Anthony L; Johnson D; Hande K; Shaff M; Winn S; Krozely M; Oates J
Acta Oncol; 1993; 32(2):217-23. PubMed ID: 7686764
[TBL] [Abstract][Full Text] [Related]
30. Long-term octreotide treatment of metastatic carcinoid tumor.
Corleto VD; Angeletti S; Schillaci O; Marignani M; Caratozzolo M; Panzuto F; Annibale B; Delle Fave G
Ann Oncol; 2000 Apr; 11(4):491-3. PubMed ID: 10847473
[TBL] [Abstract][Full Text] [Related]
31. Partial hepatic resections for metastatic neuroendocrine tumors: perioperative outcomes.
Kinney MAO; Nagorney DM; Clark DF; O'Brien TD; Turner JD; Marienau ME; Schroeder DR; Martin DP
J Clin Anesth; 2018 Dec; 51():93-96. PubMed ID: 30098573
[TBL] [Abstract][Full Text] [Related]
32. Management of patients undergoing multivalvular surgery for carcinoid heart disease: the role of the anaesthetist.
Castillo JG; Filsoufi F; Adams DH; Raikhelkar J; Zaku B; Fischer GW
Br J Anaesth; 2008 Nov; 101(5):618-26. PubMed ID: 18689806
[TBL] [Abstract][Full Text] [Related]
33. Primary hepatic carcinoid tumor with carcinoid syndrome and carcinoid heart disease: a case report of a patient on long-term follow-up.
Tohyama T; Matsui K; Kitagawa K
Intern Med; 2005 Sep; 44(9):958-62. PubMed ID: 16258211
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin Analogues in Neuroendocrine Tumors.
Kulke MH
J Natl Compr Canc Netw; 2016 Mar; 14(3):241-2. PubMed ID: 26957610
[No Abstract] [Full Text] [Related]
35. [Symptomatic treatment of the malignant carcinoid syndrome with octreotide].
Alberts AS; Falkson G
S Afr Med J; 1989 Jan; 75(1):30-1. PubMed ID: 2911781
[TBL] [Abstract][Full Text] [Related]
36. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.
Strosberg JR; Benson AB; Huynh L; Duh MS; Goldman J; Sahai V; Rademaker AW; Kulke MH
Oncologist; 2014 Sep; 19(9):930-6. PubMed ID: 25096997
[TBL] [Abstract][Full Text] [Related]
37. Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy.
Kvols LK
Am J Med; 1986 Dec; 81(6B):49-55. PubMed ID: 2432781
[TBL] [Abstract][Full Text] [Related]
38. Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid).
Davì MV; Bodei L; Francia G; Bartolomei M; Oliani C; Scilanga L; Reghellin D; Falconi M; Paganelli G; Lo Cascio V; Ferdeghini M
J Endocrinol Invest; 2006 Jun; 29(6):563-7. PubMed ID: 16840837
[TBL] [Abstract][Full Text] [Related]
39. Octreotide therapy in carcinoid disease.
Bax ND; Woods HF; Batchelor A; Jennings M
Anticancer Drugs; 1996 Jan; 7 Suppl 1():17-22. PubMed ID: 8822081
[TBL] [Abstract][Full Text] [Related]
40. Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report.
Dhanani J; Pattison DA; Burge M; Williams J; Riedel B; Hicks RJ; Reade MC
J Crit Care; 2020 Dec; 60():319-322. PubMed ID: 32928590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
